<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02773667</url>
  </required_header>
  <id_info>
    <org_study_id>I-131-07/2015</org_study_id>
    <nct_id>NCT02773667</nct_id>
  </id_info>
  <brief_title>Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine</brief_title>
  <acronym>RETENTION</acronym>
  <official_title>Relationship Between Estimated Glomerular Filtration Rate and Biological Half-life of 131I. Prospective Analysis in Patients With Differentiated Thyroid Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Correlation analysis between estimated renal function and biological half life of 131-I&#xD;
      during radioiodine treatment of patients with differentiated thyroid cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      131-I during radioiodine treatment of patients with differentiated thyroid cancer is mainly&#xD;
      renally excreted. It is advised in the clinical guidelines that serum creatinine should be&#xD;
      determined before applying 131-I and if necessary the administered dose should be reduced.&#xD;
      Nevertheless no guideline gives advice in what extent the dose should be decreased. The&#xD;
      adjustment is at the discretion of the attending physician.&#xD;
&#xD;
      Aim of this prospective study is to correlate the biological half life of 131-I with the&#xD;
      renal function to give objective recommendations concerning the reduction of the applied dose&#xD;
      in patients with limited renal function.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between estimated renal function and biological half life of 131-I</measure>
    <time_frame>2 years</time_frame>
    <description>The estimated renal function (estimated GFR) is measured via determination of serum creatinine and Cystatin C.&#xD;
The biological half-life of I-131 is determined via whole-body dosimetry (whole-body probe and whole-body gamma camera) and blood probe measurement.&#xD;
Update 2017/06/07: After analyzing the preliminary results (based on the first 48 patients) probe measurements are not longer needed in a simplified study design. Additionally, measuring the creatinine concentration is no longer needed in comparison to the Cystatin C measurements.</description>
  </primary_outcome>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Thyroid Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with histological secured differentiated thyroid cancer stationary for treatment&#xD;
        or diagnostic with radioiodine&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with differentiated thyroid carcinoma&#xD;
&#xD;
          -  stationary for treatment or diagnostic with radioiodine&#xD;
&#xD;
          -  state after thyroidectomy&#xD;
&#xD;
          -  written consent of the patient&#xD;
&#xD;
          -  minimum age 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no written consent of the patient&#xD;
&#xD;
          -  patients with large residual thyroid tissue (iodine uptake &gt; 10%)&#xD;
&#xD;
          -  children under 18 years of age&#xD;
&#xD;
          -  inclusion in concurrent interventional studies&#xD;
&#xD;
          -  patients without TSH-stimulation by rhTSH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Freesmeyer, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Freesmeyer, Dr. med.</last_name>
    <phone>+49 3641 9329805</phone>
    <email>martin.freesmeyer@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anke Werner</last_name>
    <phone>+49 3641 9329805</phone>
    <email>anke.werner@med.uni-jena.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Jena</name>
      <address>
        <city>Jena</city>
        <state>Th√ºringen</state>
        <zip>07745</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Freesmeyer, Dr. med.</last_name>
      <phone>+49 3641 9329805</phone>
    </contact>
    <contact_backup>
      <last_name>Anke Werner</last_name>
      <phone>+49 3641 9329805</phone>
      <email>Anke.Werner@med.uni-jena.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 11, 2016</study_first_submitted>
  <study_first_submitted_qc>May 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2016</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

